5-Methoxytryptophol

5-Methoxytryptophol 是一种与褪黑素 (Melatonin) (MS-N06018) 结构同源的 5-甲氧基吲哚醇,由哺乳动物松果体分泌并具有反向昼夜节律,可通过激活 ERK1/2 通路调节骨代谢,降低血清及牙髓组织中促炎细胞因子 TNF-α、IL-1β 以及蛋白水解酶 MMP-1、MMP-2 的水平以改善急性牙髓炎,还可诱导小鼠快速入睡并在高剂量下引发呼吸抑制和死亡,可用于急性牙髓炎、催眠及骨代谢相关研究。
产品编号: MS-X87902 纯度: 99.95% CAS No.: 712-09-4 分子式: C11H13NO2 分子量: 191.23
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

5-Methoxytryptophol 是一种与褪黑素 (Melatonin) (MS-N06018) 结构同源的 5-甲氧基吲哚醇,由哺乳动物松果体分泌并具有反向昼夜节律,可通过激活 ERK1/2 通路调节骨代谢,降低血清及牙髓组织中促炎细胞因子 TNF-α、IL-1β 以及蛋白水解酶 MMP-1、MMP-2 的水平以改善急性牙髓炎,还可诱导小鼠快速入睡并在高剂量下引发呼吸抑制和死亡,可用于急性牙髓炎、催眠及骨代谢相关研究。

生物实验数据

生物活性 5-Methoxytryptophol is a 5-methoxyindole alcohol structurally homologous to melatonin (Melatonin) (MS-N06018) that is secreted by the mammalian pineal gland with a reverse circadian rhythm, regulates bone metabolism via activation of the ERK1/2 pathway, ameliorates acute pulpitis by reducing the levels of pro-inflammatory cytokines TNF-α and IL-1β as well as proteolytic enzymes MMP-1 and MMP-2 in serum and dental pulp tissue, induces rapid sleep onset in mice while causing respiratory depression and death at high doses, and can be used for research on acute pulpitis, hypnosis, and bone metabolism.
IC50 & Target

Human Endogenous Metabolite

 

体外研究
(In Vitro)

5-Methoxytryptophol (0.001-2.5 mM; 24 h) 可轻度降低 MC3T3-E1 前成骨细胞的代谢活性。
5-Methoxytryptophol (0.001-2.5 mM; 48 h) 在 1 mM 和 2.5 mM 浓度下对 MC3T3-E1 成骨前体细胞具有细胞毒性,而 0.001 mM 和 0.01 mM 剂量则发挥保护作用。
5-Methoxytryptophol (0.001-2.5 mM; 14 days) 在 2.5 mM 浓度下可降低 MC3T3-E1 成骨前体细胞的总 RNA 含量。
5-Methoxytryptophol (0.001-1 mM; 14 days) 呈剂量依赖性降低 MC3T3-E1 成骨前体细胞中 Rankl 的 mRNA 表达 (低剂量下的抑制作用强于褪黑素),并在 0.1 和 1 mM 浓度下降低 Opg 的 mRNA 表达。
5-Methoxytryptophol (0.1 mM; 14 days) 可显著促进 MC3T3-E1 成骨前体细胞分泌骨钙素。
5-Methoxytryptophol (0.1 mM; 14 days) 可增强 MC3T3-E1 成骨前体细胞的矿化作用。
5-Methoxytryptophol (0.1 mM; 5 days) 可抑制受 RANKL 刺激的 RAW264.7 破骨前体细胞中多核 TRAP 阳性破骨细胞的形成。
5-Methoxytryptophol (0.1 mM; 5 days) 可降低经 RANKL 刺激的 RAW264.7 破骨前体细胞中 Mmp-9 和 CtsK 的 mRNA 表达,且不改变 Trap 的 mRNA 水平。
5-Methoxytryptophol (0.1 mM; 5 days) 可抑制经 RANKL 刺激的 RAW264.7 破骨前体细胞在牙本质切片上的骨吸收活性。
5-Methoxytryptophol (0.1 mM; 2 h) 可激活 MC3T3-E1 成骨前体细胞与 RAW264.7 破骨前体细胞中的 ERK1/2 通路 (通过上调磷酸化 ERK1/2 的表达),且该激活作用会被褪黑素受体拮抗剂 luzindole (MS-O10837) 的预处理所抑制。
5-Methoxytryptophol (0.01-10 mM; 50 min) 可抑制大鼠肝微粒体膜中的脂质过氧化,其 IC50 为 0.7 mM;0.01-3 mM 的浓度可呈剂量依赖性地维持膜流动性以抵抗氧化应激,而 10 mM 浓度虽可抑制脂质过氧化,但无法阻止膜刚性化。
5-Methoxytryptophol (0.01-10 mM; 30 min) 在 0.3-10 mM 浓度下可降低大鼠肝微粒体膜的膜流动性,且在无氧化应激的情况下不会改变脂质过氧化水平。

Cell Viability Assay

Cell Line: MC3T3-E1 preosteoblastic cells
Concentration: 0.001 mM, 0.01 mM, 0.1 mM, 1 mM, 2.5 mM
Incubation Time: 24 h
Result: Slightly reduced metabolic activity of MC3T3-E1 cells compared to vehicle control.
Showed a dose-response effect.

Cell Cytotoxicity Assay

Cell Line: MC3T3-E1 preosteoblastic cells
Concentration: 0.001 mM, 0.01 mM, 0.1 mM, 1 mM, 2.5 mM
Incubation Time: 48 h
Result: Produced significantly higher LDH release at 2.5 mM and 1 mM compared to control, indicating cytotoxicity.
Showed lower LDH release at 2.5 mM than 2.5 mM melatonin.
Reduced cell death by ≤5% at 0.001 mM and 0.01 mM doses, showing a protective effect.

Real Time qPCR

Cell Line: MC3T3-E1 preosteoblastic cells
Concentration: 0.001 mM, 0.01 mM, 0.1 mM, 1 mM
Incubation Time: 14 days
Result: Significantly decreased Rankl mRNA expression at all tested doses compared to control, with a dose-response effect where higher doses caused greater inhibition.
Decreased Rankl expression more than equivalent doses of melatonin at 0.001-0.1 mM doses.
Significantly decreased Opg mRNA expression at 0.1 mM and 1 mM compared to control.

Real Time qPCR

Cell Line: RAW264.7 preosteoclastic cells
Concentration: 0.1 mM (with 4 ng/mL RANKL co-treatment)
Incubation Time: 5 days
Result: Did not significantly change Trap mRNA levels compared to RANKL-only control.
Significantly decreased mRNA levels of functional osteoclast markers Mmp-9 and CtsK.

Immunofluorescence

Cell Line: MC3T3-E1 preosteoblastic cells, RAW264.7 preosteoclastic cells
Concentration: 0.1 mM (with 0.1 mM luzindole pre-treatment for 2 h)
Incubation Time: 2 h
Result: Increased phospho-ERK1/2 expression in both MC3T3-E1 and RAW264.7 cells to a greater degree than melatonin and vehicle control.
Pre-treatment with luzindole significantly reduced phospho-ERK1/2 expression induced by 5-MTX.
体内研究
(In Vivo)

5-Methoxytryptophol (5 mg/kg;腹腔注射;单次给药) 可显著降低脂多糖诱导的大鼠急性牙髓炎模型血清及牙髓组织中促炎细胞因子和基质金属蛋白酶的水平,并改善其组织病理学结局。
5-Methoxytryptophol (200-700 mg/kg;腹腔注射;单次给药) 可在健康 CD-1 小鼠中诱导快速入睡,平均睡眠时间在 300 mg/kg 剂量下为 5.2 min,在 600 mg/kg 剂量下为 43.9 min,其急性 LD50 约为 750 mg/kg。

Animal Model: Wistar albino rats (male and female, 200-250 g, lipopolysaccharide-induced acute pulpitis)
Dosage: 5 mg/kg
Administration: i.p.; single dose
Result: Reduced serum and pulp tissue levels of TNF-α, IL-1β, MMP-1, and MMP-2 significantly compared to the untreated acute pulpitis group.
Showed considerable histopathological improvement compared to the untreated acute pulpitis group: 50% of samples had inflammatory reaction restricted to the 60-67.5 degree region of the pulp cavity (score 4), 12.5% had inflammatory infiltrate intensity scores of 2 (20-40 cells), 50% had scores of 3 (40-60 cells), 37.5% had scores of 4 (over 60 cells), 100% had persistent inflammatory edema, 87.5% had pulp necrosis restricted to 20-30% of the 45-105 degree area (score 3), and 12.5% had over 30% necrosis (score 4).
Animal Model: CD-1 (4-6 weeks old, 16-30 grams)
Dosage: 200 mg/kg; 300 mg/kg; 400 mg/kg; 500 mg/kg; 600 mg/kg; 700 mg/kg
Administration: i.p.
Result: Showed 0 out of 6 mice slept, with 0 min sleep onset and duration at 200 mg/kg.
Induced sleep in 5 out of 6 mice, with a mean sleep onset of 2.0 min and mean sleep duration of 5.2 min at 300 mg/kg.
Induced sleep in 4 out of 6 mice, with a mean sleep onset of 1.8 min and mean sleep duration of 13.8 min at 400 mg/kg.
Induced sleep in 5 out of 6 mice, with a mean sleep onset of 1.3 min and mean sleep duration of 16.3 min at 500 mg/kg.
Induced sleep in 5 out of 6 mice, with a mean sleep onset of 1.3 min and mean sleep duration of 43.9 min at 600 mg/kg.
Induced sleep in 4 out of 6 mice (2 mice died during observation), with a mean sleep onset of 1.2 min and mean sleep duration of 38.5 min at 700 mg/kg.
Exhibited an acute LD50 of about 750 mg/kg.
性状 粘稠液体
颜色 Colorless to light yellow

化学信息

分子量 191.23
分子式 C11H13NO2
CAS No. 712-09-4

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (17.26 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Pure form -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (522.93 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM5.2293 mL26.1465 mL52.2931 mL130.7326 mL
5 mM1.0459 mL5.2293 mL10.4586 mL26.1465 mL
10 mM0.5229 mL2.6147 mL5.2293 mL13.0733 mL
15 mM0.3486 mL1.7431 mL3.4862 mL8.7155 mL
20 mM0.2615 mL1.3073 mL2.6147 mL6.5366 mL
25 mM0.2092 mL1.0459 mL2.0917 mL5.2293 mL
30 mM0.1743 mL0.8716 mL1.7431 mL4.3578 mL
40 mM0.1307 mL0.6537 mL1.3073 mL3.2683 mL
50 mM0.1046 mL0.5229 mL1.0459 mL2.6147 mL
60 mM0.0872 mL0.4358 mL0.8716 mL2.1789 mL
80 mM0.0654 mL0.3268 mL0.6537 mL1.6342 mL
100 mM0.0523 mL0.2615 mL0.5229 mL1.3073 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础